These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 32762294)

  • 1. Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report.
    Gunes AK; Demir I; Pehlivan M
    J Oncol Pharm Pract; 2021 Mar; 27(2):509-512. PubMed ID: 32762294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review.
    Zhou K; Gong D; Han Y; Huang W
    Ann Hematol; 2024 Jul; 103(7):2207-2213. PubMed ID: 37749317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
    Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
    Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
    Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
    Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
    Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J
    Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplant lymphoproliferative disorder after paediatric liver transplantation.
    Liu Y; Sun LY; Zhu ZJ; Wei L; Qu W; Wang L; Yuan LL; Zeng ZG
    Int J Clin Pract; 2021 Apr; 75(4):e13843. PubMed ID: 33222369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful nivolumab therapy in an allogeneic stem cell transplant child with post-transplant lymphoproliferative disorder.
    Kassa C; Reményi P; Sinkó J; Kállay K; Kertész G; Kriván G
    Pediatr Transplant; 2018 Dec; 22(8):e13302. PubMed ID: 30345623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of Hodgkin lymphoma-like EBV-associated post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation with nivolumab.
    Wada F; Kondo T; Nakamura M; Chonabayashi K; Nishikori M; Hishizawa M; Yamashita K; Takaori-Kondo A
    Ann Hematol; 2020 Apr; 99(4):887-889. PubMed ID: 32052134
    [No Abstract]   [Full Text] [Related]  

  • 9. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
    Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
    Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen.
    Okeleji O; Gibson A; Nunez C; Garcia MB; Roth M; Cuglievan B; McCall D
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31091. PubMed ID: 38840433
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
    Vijenthira A; Chan K; Cheung MC; Prica A
    Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.
    Abramson JS; Arnason JE; LaCasce AS; Redd R; Barnes JA; Sokol L; Joyce R; Avigan D; Neuberg D; Takvorian RW; Hochberg EP; Bello CM
    Blood; 2019 Aug; 134(7):606-613. PubMed ID: 31186274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules.
    Kampers J; Orjuela-Grimm M; Schober T; Schulz TF; Stiefel M; Klein C; Körholz D; Mauz-Körholz C; Kreipe H; Beier R; Maecker-Kolhoff B
    Leuk Lymphoma; 2017 Mar; 58(3):633-638. PubMed ID: 27685149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage IV Classical Hodgkin Lymphoma-type Posttransplant Lymphoproliferative Disorder in a Pediatric Liver Transplant Patient: A Case Report and Review of the Literature.
    Choi S; Hong KT; Choi JY; Ahn HY; Ko JS; Suh KS; Park SH; Cheon JE; Shin HY; Kang HJ
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e1015-e1019. PubMed ID: 33769384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced stages of classical Hodgkin lymphoma - first-line treatment options.
    Mociková H
    Klin Onkol; 2021; 34(6):450-454. PubMed ID: 34911330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
    Straus DJ; Długosz-Danecka M; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Connors JM; Radford J; Munoz J; Kim WS; Advani R; Ansell SM; Younes A; Miao H; Liu R; Fenton K; Forero-Torres A; Gallamini A
    Blood; 2020 Mar; 135(10):735-742. PubMed ID: 31945149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
    de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
    Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.
    Connors JM; Ansell SM; Fanale M; Park SI; Younes A
    Blood; 2017 Sep; 130(11):1375-1377. PubMed ID: 28733323
    [No Abstract]   [Full Text] [Related]  

  • 20. Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD.
    Minson A; Douglas G; Bilmon I; Grigg A
    Br J Haematol; 2019 Mar; 184(5):840-844. PubMed ID: 29532918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.